Genedrive (GB:GDR) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genedrive PLC, a leading pharmacogenetic testing company, has announced a slight delay in the expected publication date by the UK’s National Institute for Health and Care Excellence (NICE) for its CYP2C19 genotyping test used in guiding clopidogrel treatment after strokes. The new release date is now set for 31 July 2024, pushed back from the previously anticipated 10 July. The CYP2C19-ID test is recognized as the preferred choice for point-of-care strategies, emphasizing Genedrive’s role in pioneering rapid and effective pharmacogenetic diagnostics.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.